Apellis Pharmaceuticals, Inc. (APLS)

Latest Insider Confidence Score

2026Q1

42.4
Bearish

Company insider confidence (by quarter)

2018Q2 2026Q1

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Morningside Venture Investments Ltd 10% Owner 12,806,342 Nov 18, 2021
Dunlop A. Sinclair Director 158,393 Oct 2, 2025
Grossi Federico Chief Medical Officer 94,884 Jan 9, 2023
Baumal Caroline Chief Medical Officer 93,301.37 Jan 21, 2025
Meltzer Leslie — 92,592 Sep 2, 2025

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Feb 27, 2026 Mar 3, 2026 Dolsten Mikael Director Neutral 90.0 +14,312 100.00% ✗ -
Mar 3, 2026 Dolsten Mikael Director Neutral 52.5 - 0.00% ✗ -
Feb 11, 2026 Feb 13, 2026 DeLong Mark Jeffrey Chief Business & Strat Officer Sell 52.5 -368 -0.32% ✗ $8.2K
Feb 3, 2026 Feb 5, 2026 Francois Cedric CEO Neutral 52.5 - 0.00% ✗ -
Jan 28, 2026 Jan 30, 2026 Boucher Kelley Chief People Officer Neutral 90.0 +30,146 30.87% ✗ -
Jan 28, 2026 Jan 30, 2026 Chopas James George VP/Chief Accounting Officer Neutral 90.0 +16,150 32.43% ✗ -
Jan 28, 2026 Jan 30, 2026 DeLong Mark Jeffrey Chief Business & Strat Officer Neutral 90.0 +36,606 46.72% ✗ -
Jan 28, 2026 Jan 30, 2026 Deschatelets Pascal Chief Scientific Officer Neutral 77.5 +25,840 2.24% ✗ -
Jan 28, 2026 Jan 30, 2026 MELTZER LESLIE Chief Research and Development Neutral 90.0 +45,220 73.17% ✗ -
Jan 28, 2026 Jan 30, 2026 Nicholson Nur Chief Technical Officer Neutral 90.0 +45,220 63.58% ✗ -
Jan 28, 2026 Jan 30, 2026 Sullivan Timothy Eugene CFO Neutral 90.0 +58,140 37.68% ✗ -
Jan 28, 2026 Jan 30, 2026 Watson David O. General Counsel Neutral 90.0 +55,986 37.66% ✗ -
Jan 28, 2026 Jan 30, 2026 Francois Cedric CEO Neutral 90.0 +195,952 12.24% ✗ -
Jan 22, 2026 Jan 23, 2026 Baumal Caroline Chief Medical Officer Sell 42.5 -2,797 -3.13% ✗ $60.9K
Jan 22, 2026 Jan 23, 2026 Chopas James George VP/Chief Accounting Officer Sell 46.3 -2,064 -3.98% ✗ $44.9K
Jan 22, 2026 Jan 23, 2026 DeLong Mark Jeffrey Chief Business & Strat Officer Sell 42.5 -3,371 -4.12% ✗ $73.4K
Jan 22, 2026 Jan 23, 2026 Deschatelets Pascal Chief Scientific Officer Sell 45.0 -5,928 -0.51% ✗ $129K
Jan 22, 2026 Jan 23, 2026 Francois Cedric CEO Sell 40.0 -27,192 -1.67% ✗ $591.8K
Jan 22, 2026 Jan 23, 2026 Nicholson Nur Chief Technical Officer Sell 42.5 -7,725 -9.80% ✗ $168.1K
Jan 22, 2026 Jan 23, 2026 Sullivan Timothy Eugene CFO Sell 42.5 -10,287 -6.25% ✗ $223.9K
Jan 22, 2026 Jan 23, 2026 Watson David O. General Counsel Sell 42.5 -7,832 -5.00% ✗ $170.5K
Jan 20, 2026 Jan 21, 2026 Baumal Caroline Chief Medical Officer Sell 46.3 -1,882 -2.06% ✗ $37.3K
Jan 20, 2026 Jan 21, 2026 Chopas James George VP/Chief Accounting Officer Sell 46.3 -726 -1.38% ✗ $14.4K
Jan 20, 2026 Jan 21, 2026 DeLong Mark Jeffrey Chief Business & Strat Officer Sell 46.3 -1,334 -1.61% ✗ $26.4K
Jan 20, 2026 Jan 21, 2026 Deschatelets Pascal Chief Scientific Officer Sell 51.3 -909 -0.08% ✗ $18K
Jan 20, 2026 Jan 21, 2026 Francois Cedric CEO Sell 45.0 -8,182 -0.50% ✗ $161.9K
Jan 20, 2026 Jan 21, 2026 Nicholson Nur Chief Technical Officer Sell 46.3 -2,203 -2.72% ✗ $43.6K
Jan 20, 2026 Jan 21, 2026 Sullivan Timothy Eugene CFO Sell 42.5 -2,892 -1.73% ✗ $57.2K
Jan 20, 2026 Jan 21, 2026 Watson David O. General Counsel Sell 46.3 -2,475 -1.56% ✗ $49K
Jan 13, 2026 Jan 15, 2026 Chopas James George VP/Chief Accounting Officer Sell 46.3 -873 -1.63% ✗ $19.4K
Jan 13, 2026 Jan 15, 2026 DeLong Mark Jeffrey Chief Business & Strat Officer Sell 46.3 -1,780 -2.10% ✗ $39.5K
Jan 13, 2026 Jan 15, 2026 Deschatelets Pascal Chief Scientific Officer Sell 47.5 -2,277 -0.20% ✗ $50.5K
Jan 13, 2026 Jan 15, 2026 Francois Cedric CEO Sell 45.0 -10,186 -0.62% ✗ $226K
Jan 13, 2026 Jan 15, 2026 Nicholson Nur Chief Technical Officer Sell 42.5 -2,618 -3.13% ✗ $58.1K
Jan 13, 2026 Jan 15, 2026 Sullivan Timothy Eugene CFO Sell 42.5 -3,856 -2.25% ✗ $85.6K
Jan 13, 2026 Jan 15, 2026 Watson David O. General Counsel Sell 42.5 -5,780 -3.51% ✗ $128.2K
Jan 7, 2026 Jan 9, 2026 Watson David O. General Counsel Neutral 52.5 - 0.00% ✗ -
Jan 5, 2026 Jan 6, 2026 Baumal Caroline Chief Medical Officer Sell 42.5 -3,020 -3.21% ✗ $77.1K
Jan 1, 2026 Jan 5, 2026 Machiels Alec Director Neutral 77.5 +7,961 1.01% ✗ -
Jan 1, 2026 Jan 5, 2026 Dunlop A. Sinclair Director Neutral 85.0 +7,961 5.18% ✗ -
Jan 1, 2026 Jan 5, 2026 Chan Gerald Director Neutral 90.0 +7,961 44.96% ✗ -
Jan 1, 2026 Jan 5, 2026 O'Brien Stephanie Monaghan Director Neutral 90.0 +7,961 44.96% ✗ -
Jan 1, 2026 Jan 5, 2026 FONTEYNE PAUL R. Director Neutral 90.0 +7,961 35.06% ✗ -
Jan 1, 2026 Jan 5, 2026 Walbert Keli Director Neutral 90.0 +7,961 87.58% ✗ -
Jan 1, 2026 Jan 5, 2026 WHEELER CRAIG A Director Neutral 90.0 +7,961 48.30% ✗ -
Dec 16, 2025 Dec 18, 2025 Watson David O. General Counsel Sell 41.3 -5,000 -2.96% ✓ $122.5K
Nov 17, 2025 Nov 18, 2025 Watson David O. General Counsel Sell 41.3 -5,000 -2.88% ✓ $100.3K
Oct 21, 2025 Oct 23, 2025 Sullivan Timothy Eugene CFO Sell 30.0 -10,000 -5.51% ✓ $280.3K
Oct 16, 2025 Oct 17, 2025 Watson David O. General Counsel Sell 41.3 -5,000 -2.80% ✓ $126.1K
Jun 24, 2025 Oct 15, 2025 Dunlop A. Sinclair Director Sell 12.5 -39,716 -20.54% ✓ $737.5K
Sep 30, 2025 Oct 2, 2025 Dunlop A. Sinclair Director Sell 17.5 -34,929 -15.63% ✓ $702.1K
Sep 19, 2025 Sep 19, 2025 Dunlop A. Sinclair Director Sell 22.5 -34,929 -13.52% ✓ $713.6K
Sep 16, 2025 Sep 18, 2025 Watson David O. General Counsel Sell 41.3 -5,000 -2.72% ✓ $121.7K
Sep 15, 2025 Sep 17, 2025 Chopas James George VP/Chief Accounting Officer Sell 52.5 -189 -0.35% ✗ $4.6K
Sep 10, 2025 Sep 12, 2025 Watson David O. General Counsel Sell 20.0 -20,000 -9.81% ✗ $523.4K
Sep 8, 2025 Sep 10, 2025 Sullivan Timothy Eugene CFO Sell 15.0 -42,729 -19.96% ✓ $1.2M
Sep 2, 2025 Sep 3, 2025 Chopas James George VP/Chief Accounting Officer Sell 46.3 -548 -1.01% ✗ $15.4K
Sep 2, 2025 Sep 3, 2025 Boucher Kelley Chief People Officer Neutral 90.0 +30,476 45.36% ✗ -
Aug 26, 2025 Sep 2, 2025 MELTZER LESLIE Chief Research and Development Neutral 90.0 +61,804 100.00% ✗ -
Sep 2, 2025 MELTZER LESLIE Chief Research and Development Neutral 52.5 - 0.00% ✗ -
Aug 27, 2025 Aug 29, 2025 Francois Cedric CEO Sell 16.3 -225,000 -12.03% ✗ $6.4M
Aug 18, 2025 Aug 19, 2025 Watson David O. General Counsel Sell 41.3 -5,000 -2.39% ✓ $139K
Jul 17, 2025 Jul 18, 2025 Francois Cedric CEO Sell 42.5 -19,725 -1.04% ✓ $398.7K
Jul 16, 2025 Jul 18, 2025 Watson David O. General Counsel Sell 41.3 -5,000 -2.34% ✓ $97.8K
Jul 14, 2025 Jul 16, 2025 Francois Cedric CEO Sell 27.5 -139,365 -5.89% ✓ $2.8M
Jun 18, 2025 Jun 20, 2025 Chopas James George VP/Chief Accounting Officer Neutral 90.0 +6,250 13.03% ✗ -
Jun 16, 2025 Jun 18, 2025 Watson David O. General Counsel Sell 41.3 -5,000 -2.28% ✓ $93.9K
Jun 9, 2025 Jun 11, 2025 Boucher Kelley Chief People Officer Neutral 90.0 +45,095 204.17% ✗ -
Jun 9, 2025 Jun 11, 2025 Watson David O. General Counsel Neutral 52.5 - 0.00% ✗ -
Jun 9, 2025 Jun 11, 2025 Nicholson Nur Chief Technical Officer Neutral 52.5 - 0.00% ✗ -
Jun 9, 2025 Jun 11, 2025 Francois Cedric CEO Neutral 52.5 - 0.00% ✗ -
Jun 9, 2025 Jun 11, 2025 Sullivan Timothy Eugene CFO Neutral 52.5 - 0.00% ✗ -
Jun 9, 2025 Jun 11, 2025 Deschatelets Pascal Chief Scientific Officer Neutral 52.5 - 0.00% ✗ -
Jun 9, 2025 Jun 11, 2025 Baumal Caroline Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Jun 9, 2025 Jun 11, 2025 Chopas James George VP/Chief Accounting Officer Neutral 52.5 - 0.00% ✗ -
Jun 9, 2025 Jun 11, 2025 DeLong Mark Jeffrey Chief Business & Strat Officer Neutral 52.5 - 0.00% ✗ -
May 28, 2025 May 29, 2025 Boucher Kelley Chief People Officer Neutral 90.0 +22,087 100.00% ✗ -
May 29, 2025 Boucher Kelley Chief People Officer Neutral 52.5 - 0.00% ✗ -
May 21, 2025 May 22, 2025 Deschatelets Pascal Chief Scientific Officer Neutral 52.5 - 0.00% ✗ -
Apr 17, 2025 Apr 21, 2025 WHEELER CRAIG A Director Neutral 90.0 +16,483 100.00% ✗ -
Apr 21, 2025 WHEELER CRAIG A Director Neutral 52.5 - 0.00% ✗ -
Mar 17, 2025 Mar 18, 2025 Chopas James George VP/Chief Accounting Officer Sell 52.5 -183 -0.38% ✗ $4.5K
Mar 4, 2025 Mar 6, 2025 Watson David O. General Counsel Sell 22.5 -5,569 -2.48% ✗ $139.8K
Feb 11, 2025 Feb 12, 2025 DeLong Mark Jeffrey Chief Business & Strat Officer Sell 51.3 -363 -0.43% ✗ $10.4K
Jan 29, 2025 Jan 30, 2025 Watson David O. General Counsel Sell 51.3 -695 -0.31% ✗ $20.5K
Jan 29, 2025 Jan 30, 2025 Townsend Adam J. Chief Commercial Officer Sell 48.8 -695 -0.82% ✗ $20.5K
Jan 29, 2025 Jan 30, 2025 Sullivan Timothy Eugene CFO Sell 51.3 -546 -0.27% ✗ $16.1K
Jan 29, 2025 Jan 30, 2025 Nicholson Nur Chief Technical Officer Sell 48.8 -825 -0.98% ✗ $24.4K
Jan 29, 2025 Jan 30, 2025 Lewis Karen Chief People Officer Sell 48.8 -364 -0.52% ✗ $10.7K
Jan 29, 2025 Jan 30, 2025 Eisele Jeffrey Chief Development Officer Sell 50.0 -278 -0.50% ✗ $8.2K
Jan 29, 2025 Jan 30, 2025 Deschatelets Pascal Chief Scientific Officer Sell 51.3 -826 -0.07% ✗ $24.4K
Jan 29, 2025 Jan 30, 2025 Francois Cedric CEO Sell 47.5 -2,824 -0.14% ✗ $83.4K
Jan 29, 2025 Jan 30, 2025 DeLong Mark Jeffrey Chief Business & Strat Officer Sell 51.3 -365 -0.43% ✗ $10.8K
Jan 22, 2025 Jan 23, 2025 Watson David O. General Counsel Sell 42.5 -3,323 -1.45% ✗ $101.1K
Jan 22, 2025 Jan 23, 2025 Townsend Adam J. Chief Commercial Officer Sell 42.5 -3,323 -3.77% ✗ $101.1K
Jan 22, 2025 Jan 23, 2025 Sullivan Timothy Eugene CFO Sell 42.5 -3,088 -1.52% ✗ $94K
Jan 22, 2025 Jan 23, 2025 Nicholson Nur Chief Technical Officer Sell 42.5 -3,948 -4.46% ✗ $120.1K
Jan 22, 2025 Jan 23, 2025 Lewis Karen Chief People Officer Sell 42.5 -1,751 -2.42% ✗ $53.3K
Jan 22, 2025 Jan 23, 2025 Francois Cedric CEO Sell 42.5 -13,551 -0.69% ✗ $412.3K
Jan 22, 2025 Jan 23, 2025 Eisele Jeffrey Chief Development Officer Sell 46.3 -1,291 -2.27% ✗ $39.3K